Table 4.

Associations of randomized treatment groups with TNFR1 and TNFR2 slopes in AASK (n=435) and changes in VA NEPHRON-D (n=759)

AASK Randomized Treatment Groups	Unadjusted (n=435)	Adjusted for Biomarker Level at t0a (n=435)	Fully Adjusted Modelb (n=435)
	% Change (95% CI)	% Change (95% CI)	% Change (95% CI)
TNFR1 slope
BP goal
Intensive	Ref	Ref	Ref
Standard	−0.41 (−1.98 to 1.19)	−0.65 (−2.02 to 0.73)	−0.68 (−1.98 to 0.63)
BP drug
Ramipril	Ref	Ref	Ref
Metoprolol	1.07 (−0.71 to 2.88)	1.33 (−0.22 to 2.91)	1.16 (−0.29 to 2.64)
Amlodipine	1.55 (−0.66 to 3.80)	1.61 (−0.32 to 3.57)	1.91 (0.10 to 3.75)
TNFR2 slope
BP goal
Intensive	Ref	Ref	Ref
Standard	−0.27 (−1.45 to 0.92)	−0.39 (−1.45 to 0.67)	−0.38 (−1.37 to 0.62)
BP drug
Ramipril	Ref	Ref	Ref
Metoprolol	0.73 (−0.59 to 2.07)	0.88 (−0.31 to 2.09)	0.83 (−0.29 to 1.95)
Amlodipine	0.67 (−0.96 to 2.33)	0.87 (−0.60 to 2.36)	0.93 (−0.44, 2.32)
VA NEPHRON-D Randomized Treatment Groups	Unadjusted (n=759)	Adjusted for biomarker level at t0a (n=759)	Fully adjusted modelc (n=747)
	% change (95% CI)	% change (95% CI)	% change (95% CI)
TNFR1 change
Losartan	Ref	Ref	Ref
Losartan + lisinopril	4.02 (−1.42 to 9.77)	3.78 (−1.31 to 9.13)	2.01 (−2.60 to 6.84)
TNFR2 change
Losartan	Ref	Ref	Ref
Losartan + lisinopril	1.24 (−2.32 to 4.93)	1.21 (−2.32 to 4.85)	0.78 (−2.63 to 4.31)

% change determined by exponentiating β coefficients as follows: [e^β-1] x 100. Ref, reference.

^aAdjusted for ln(biomarker) at 0 months.

^bAdjusted for ln(biomarker), age, sex, systolic BP, body mass index, smoking, GFR, and ln(UPCR) at 0 months.

^cAdjusted for ln(biomarker), age, sex, race, systolic BP, body mass index, smoking, hemoglobin A1c, eGFR, and ln(UACR) at 0 months.